In the mid‐2010s, Schaal et al.83, 84noted that patients with age‐related macular degeneration (AMD) or DMO were more likely to have poor response to anti‐vascular endothelial growth factor (VEGF) therapy if they had symptoms of OSA or untreated OSA. This evidence concerns the gene VEGFA and age-related macular degeneration.